Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (U01 NS041588)
Agency for Healthcare Research and Quality (T32HS000066)
Received: 8 May 2017
Accepted: 11 April 2018
First Online: 16 April 2018
Ethics approval and consent to participate
: The study protocol was reviewed and approved by the University of Alabama at Birmingham Institutional Review Board and all participants provided written informed consent.
: Dr. Durant receives support from Amgen related to the treatment of heart failure. He also receives research grant funding from Amarin related to primary and secondary prevention of myocardial infarction. Dr. Levitan receives research grants from Amgen related to treatment of heart failure and other cardiovascular disease (significant) and does consulting for Amgen and Novartis related to treatment of heart failure (modest). Dr. Brown receives Amgen support for research related to heart failure. Dr. Safford receives salary support for investigator-initiated research from Amgen, Inc. All other authors have no conflicts or competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.